1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Shandong Weigao Orthopaedic Device Co., Ltd. Class A

Shandong Weigao Orthopaedic Device Co., Ltd. Class A

SSSE:688161
22.08
CNY
+0.71
(+3.32%)
8.39BMarket Cap
Oct 31Next Earn
Shandong Weigao Orthopaedic Device Co., Ltd. Class A
SSE:688161
(Shanghai Stock Exchange)

Recent

price

22.08

P/E

ratio

- -

div

yld

1.37%

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
4.07
5.45
4.74
5.1
5.68
5.14
3.2
3.64
3.85
- -
Revenue per Share
0.91
1.46
1.33
1.56
1.82
1.5
0.28
0.56
0.68
- -
Basic EPS, GAAP
0.96
1.22
1.52
1.66
1.78
0.98
0.19
0.63
0.98
- -
Free Cash Flow per Basic Share
- -
- -
- -
2.23
- -
0.53
0.41
0.19
0.32
0.3
Dividend per Share
6.33
7.78
5.22
6.84
11.33
12.51
9.67
9.88
10.36
10.49
Book Value per Share
5.71
7.19
4.87
6.55
11.08
12.26
9.3
9.55
10.05
9.92
Tangible Book Value per Share
223
222
332
358
379
400
401
400
395
398
Basic Weighted Avg Shares
906
1,211
1,574
1,824
2,154
2,058
1,284
1,453
1,523
- -
Sales/Revenue/Turnover
29.82
32.63
100
37.14
36.39
31.9
7.15
17.56
21.09
- -
Operating Margin (%)
33
38
7
42
51
57
62
65
67
- -
Depreciation Expense
203
324
442
558
690
601
112
224
269
- -
Net Income, GAAP
20.13
16.1
13.83
15.66
14.64
14.99
14.08
15.74
15.51
- -
Effective Tax Rate (%)
22.38
26.78
28.06
30.62
32.05
29.19
8.75
15.4
17.64
- -
Profit Margin (%)
905
1,216
1,370
1,935
3,965
4,360
3,177
3,333
3,445
3,078
Working Capital
- -
- -
- -
10
12
10
6
2
9
6
LT Debt
1,413
1,743
1,879
2,464
4,538
5,006
3,874
3,963
4,159
4,229
Total Equity
- -
20.33
24.11
25.37
19.45
12.43
2.52
5.85
6.69
- -
Return on Invested Capital (%)
- -
20.16
23.76
25
19.62
12.57
2.52
5.6
6.47
- -
Return on Capital (%)
- -
20.68
24.53
25.82
19.76
12.6
2.53
5.72
6.63
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
29
34
33
LT Borrowings
- -
- -
- -
LT Finance Leases
9
8
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
400
400
400
Market Capitalization
11,168
12,316
8,392

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,308
4,340
4,005
Cash, Cash Equivalents & STI
1,679
1,662
1,479
Accounts Receivable, Net
289
321
379
Inventories
589
625
623
Total Current Liabilities
863
912
927
Payables & Accruals
- -
- -
- -
ST Debt
29
34
33
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
15.82%
4.95%
Free Cash Flow
- -
34.69%
55.42%
Net Income, GAAP
- -
9.72%
20.06%
Sales/Revenue/Turnover
- -
-1.2%
4.82%
Total Cash Common Dividend
- -
- -
69.67%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
348
403
333
369
1,453
2025
290
451
- -
417
1,523
2026
296
408
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.15
0.18
0.15
0.56
2025
0.13
0.23
- -
0.15
0.68
2026
0.11
0.22
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.1
0.07
0.19
2025
- -
- -
- -
0.1
0.32
2026
- -
0.2
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Shandong Weigao Orthopaedic Device Co., Ltd. is a China-based medical technology company that researches, develops, manufactures, and distributes orthopedic implantable medical devices, surgical instruments, and related clinical solutions. The company operates across several specialized product segments, providing a comprehensive portfolio that includes: spinal fixation systems, such as anterior and posterior cervical plates, thoracic and lumbar pedicle screws, dynamic stabilization systems, and interbody fusion cages; trauma fixation devices, including anatomical locking plates, intramedullary nails, cannulated screws, and external fixation frames; artificial joint prostheses, featuring total hip replacement systems, total knee arthroplasty implants, and shoulder prostheses; sports medicine products, such as suture anchors, interference screws, and specialized instruments for cruciate ligament reconstruction and meniscus repair; bone repair biomaterials, encompassing synthetic bone graft substitutes and platelet-rich plasma preparation kits; and minimally invasive and digital surgery instruments, including surgical power tools, customized orthopedic kits, diagnostic devices, and surgical navigation and robotic integration accessories. The company markets its products under primary brand names including WEGO Ortho, Yahua, Jianli Bond, and Starfish Medical, serving tertiary and secondary hospitals, specialized orthopedic centers, and medical institutions through an extensive distribution network spanning over 2,300 distributors and 4,500 healthcare facilities across China, as well as export markets throughout Europe, Southeast Asia, the Middle East, Africa, and Latin America. In recent developments, Shandong Weigao Orthopaedic Device Co., Ltd. has strategically accelerated the expansion of its non-centralized procurement business lines, prioritizing investments in high-growth segments such as sports medicine, regenerative biomaterials, and robotic-assisted surgical applications to diversify revenue streams. The company implemented a share repurchase program to optimize capital structure and reinforce shareholder value. In addition, aligned with Weigao Group's broader platform integration and global expansion strategy, the company has broadened its international regulatory compliance, obtaining additional CE and ISO certifications to advance its overseas market penetration and cross-border commercial partnerships. Founded in 2005, Shandong Weigao Orthopaedic Device Co., Ltd. is headquartered in Weihai, Shandong Province, China, and operates as a publicly traded subsidiary of Shandong Weigao Group Medical Polymer Company Limited.